<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717714</url>
  </required_header>
  <id_info>
    <org_study_id>Polycan-VN01</org_study_id>
    <nct_id>NCT03717714</nct_id>
  </id_info>
  <brief_title>Polycan in Combination With Glucosamine for Treatment of Knee Osteoarthritis</brief_title>
  <official_title>A Randomized, Double-blind, Active Controlled, 12-week Follow-up, Pilot Study to Evaluate the Safety and Efficacy of Polycan in Combination With Glucosamine for Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vietstar Biomedical Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vietstar Biomedical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to examine the Safety and Eï¬ƒcacy of black yeast beta-glucan
      produced from Aureobusidium pulluluns SM-2001 (Polycan), in combination with glucosamine in
      reducing knee osteoarthritis (OA) associated symptoms. This study is a double-blind,
      randomized, active-controlled trial conducted with 100 OA patients, aged 35-80 years using a
      formulated product
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) changes at 12 weeks in the three groups</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The WOMAC consists of 24 items divided into 3 subscales:
Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing Stiffness (2 items): after first waking and later in the day Physical Function (17 items): stair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties.
Total WOMAC score ranges from 0 to 96 with higher scores indicate worse pain, stiffness, and functional limitations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dose of rescue medication (Meloxicam 7.5mg) used in the three groups.</measure>
    <time_frame>Through study completion, an average of 12 weeks</time_frame>
    <description>Rescue medication (Meloxicam 7.5mg) used by patients for 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Glucosamine 1500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucosamine 1500 mg per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polycan &amp; Glucosamine 750mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polycan 50 mg + Glucosamine 750 mg per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polycan &amp; Glucosamine 1500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polycan 50 mg + Glucosamine 1500 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucosamine 1500 mg</intervention_name>
    <description>Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks</description>
    <arm_group_label>Glucosamine 1500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polycan 50mg + Glucosamine 750 mg</intervention_name>
    <description>Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks</description>
    <arm_group_label>Polycan &amp; Glucosamine 750mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polycan 50mg + Glucosamine 1500 mg</intervention_name>
    <description>Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks</description>
    <arm_group_label>Polycan &amp; Glucosamine 1500mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of knee osteoarthritis (OA)

          -  OA ranging from grade 1 to grade 3 by Kellgren and Lawrence system

          -  Agree to participate into the study

        Exclusion Criteria:

          -  OA ranging from grade 4 by Kellgren and Lawrence system

          -  Allergic or contradicted with oral NSAIDs (Meloxicam)

          -  Pregnant and breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>198 Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

